<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="?"><plain>CLINICAL QUESTION: Which <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs provide optimal weight control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> reduces <z:mp ids='MP_0005456'>weight gain</z:mp>, and may cause <z:hpo ids='HP_0001824'>weight loss</z:hpo>, when given alone or in combination with other drugs </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> use is associated with <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Use of the glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) analogs, liraglutide and exenatide, is associated with <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral </plain></SENT>
<SENT sid="5" pm="."><plain>Results with insulin therapy are conflicting </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin detemir provides weight control along with glycemic control </plain></SENT>
<SENT sid="7" pm="."><plain>IMPLEMENTATION: <z:mp ids='MP_0005456'>Weight gain</z:mp> is considered an inevitable part of good glycemic control using conventional modalities of treatment such as <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>.1Use of <z:chebi fb="0" ids="6801">metformin</z:chebi>, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs </plain></SENT>
</text></document>